Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

Lyon-II, 3000 - Ticlopidine vs placebo

Gardecki, 3000 - Ticlopidine vs placebo

ADVANCE 2, 2010 - apixaban vs enoxaparin (europe regimen)

ADVANCE 3, 2010 - apixaban vs enoxaparin

RECORD 4, 2009 - rivaroxaban vs enoxaparin (US regimen)

WATCH (warfarin vs aspirin), 2009 - warfarin vs aspirin

RECORD 2, 2008 - rivaroxaban (long duration) vs enoxaparin (short duration)

RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin (US regimen)

ADVANCE-1, 2008 - apixaban vs enoxaparin (US regimen)

RECORD 1, 2008 - rivaroxaban vs enoxaparin

DRIVE, 2008 - SR123781A vs enoxaparin

RECORD 3, 2008 - rivaroxaban vs enoxaparin (europe regimen)

RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin (US regimen)

RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin (europe regimen)

RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin

APROPOS 2.5mg, 2007 - apixaban vs enoxaparin (US regimen)

RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin (europe regimen)

RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin

Cohen (L8405), 2007 - compression stocking group vs control (on top fondaparinux)

HELAS (warfarin vs aspirin), 2006 - warfarin vs aspirin

ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin (short duration)

ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin (US regimen)

WASH (warfarin), 2004 - warfarin vs no treatment

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 - triflusal+coumadin medium dose vs triflusal

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 - triflusal+coumadin medium dose vs coumadin standard dose



See also:

  • All DVT prophylaxis clinical trials
  • All clinical trials of new anticoagulants
  • All clinical trials of dabigatran 150mg
  •  

    RE-MODEL (150mg) study, 2007

    Facebook    pdf : dabigatran 150mg - antithrombotics for DVT prophylaxis

    Treatments

    Studied treatment dabigatran etexilate 150 mg q.d. for 6-10 days
    administered 1–4 h after completion of surgery
    Control treatment Enoxaparin 40 mg q.d. for 6-10 days
    started on the evening before surgery
    Treatments description
    enoxaprin regimen started before surgery  
    treatment duration 6-10 days 

    Patients

    Patients Total knee replacement
    Inclusion criteria Patients <=18 years; >40 kg; scheduled for primary elective unilateral total knee replacement
    Exclusion criteria any bleeding diathesis; history of acute intracranial disease or hemorrhagic stroke; major surgery, trauma, uncontrolled hypertension or myocardial infarction within the past 3 months; gastrointestinal or urogenital bleeding or ulcer disease within the past 6 months; severe liver disease; aspartate aminotransferase or alanine aminotransferase (ALT) levels more than two times the upper limit of the normal range (ULN) within the past month; severe renal insufficiency (creatinine clearance <30 mL/min); concomitant long-acting non-steroidal anti-inflammatory drug therapy (also contraindicated during study treatment); active malignant disease
    Baseline characteristics
    Age (mean), years 68y 
    Total hip replacement 0% 
    Total knee replacement 100% 
    Weight, kg, 82 kg 
    Female 67% 
    general anesthesia 23% 
    BMI (kg/m²) NA 
    History of venous thromboembolism (%) NA 
    Use of cement NA 
    Estimated creatinine clearance >60 ml/min NA 
    Previous orthopedic surgery (%) NA 
    Duration of surgery (min) 91 min 

    Method and design

    Randomized effectives 708 / 699 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 6-10 days, mean 8 days
    Number of centre 105
    Geographic area Europe, Australia, South Africa
    Hypothesis Non inferiority
    Primary endpoint total VTE and all-cause mortality
    Remarks

    Remarks / Comments



    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    major or clinically relevant non-major bleeding

    57 / 703
    46 / 694
    1,22 [0,84;1,78]

    All cause death

    1 / 696
    1 / 685
    classic 0,98 [0,06;15,70]

    asymptomatic DVT

    208 / 526
    184 / 512
    1,10 [0,94;1,29]

    non-fatal pulmonary embolism

    1 / 526
    0 / 512
    classic 4,87 [0,07;355,98]

    proximal DVT

    18 / 526
    17 / 512
    1,03 [0,54;1,98]

    Major bleeding

    9 / 703
    9 / 694
    classic 0,99 [0,39;2,47]

    total VTE and all-cause mortality

    213 / 526
    193 / 512
    1,07 [0,92;1,25]

    Symptomatic deep-vein thrombosis

    3 / 526
    8 / 512
    0,37 [0,10;1,37]

    distal DVT

    193 / 526
    175 / 512
    1,07 [0,91;1,27]

    major VTE (fatal and non fatal DVT,PE)

    20 / 527
    18 / 511
    classic 1,08 [0,58;2,01]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    major or clinically relevant non-major bleeding 57 / 703 (8,1%) 46 / 694 (6,6%) 1,22 [0,84;1,78]   12100 
    All cause death 1 / 696 (0,1%) 1 / 685 (0,1%) 0,98 [0,06;15,70]   12100 
    asymptomatic DVT 208 / 526 (39,5%) 184 / 512 (35,9%) 1,10 [0,94;1,29]    
    non-fatal pulmonary embolism 1 / 526 (0,2%) 0 / 512 (0,1%) 1,95 [0,07;57,91]    
    proximal DVT 18 / 526 (3,4%) 17 / 512 (3,3%) 1,03 [0,54;1,98]    
    Major bleeding 9 / 703 (1,3%) 9 / 694 (1,3%) 0,99 [0,39;2,47]   12100 
    total VTE and all-cause mortality 213 / 526 (40,5%) 193 / 512 (37,7%) 1,07 [0,92;1,25]    
    Symptomatic deep-vein thrombosis 3 / 526 (0,6%) 8 / 512 (1,6%) 0,37 [0,10;1,37]    
    distal DVT 193 / 526 (36,7%) 175 / 512 (34,2%) 1,07 [0,91;1,27]    
    major VTE (fatal and non fatal DVT,PE) 20 / 527 (3,8%) 18 / 511 (3,5%) 1,08 [0,58;2,01]   12100 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 12100: Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HROral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.J Thromb Haemost 2007;5:2178-85

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    major or clinically relevant non-major bleeding 8,11% 6,63% 1,5%
    All cause death 1,44‰ 1,46‰ -0,0‰
    asymptomatic DVT 39,54% 35,94% 3,6%
    proximal DVT 3,42% 3,32% 1,0‰
    Major bleeding 1,28% 1,30% -0,2‰
    total VTE and all-cause mortality 40,49% 37,70% 2,8%
    Symptomatic deep-vein thrombosis 5,70‰ 1,56% -9,9‰
    distal DVT 36,69% 34,18% 2,5%
    major VTE (fatal and non fatal DVT,PE) 3,80% 3,52% 2,7‰

    Meta-analysis of all similar trials:

    anticoagulant in DVT prophylaxis for orthopedic surgery

    antithrombotics in DVT prophylaxis for elective major knee surgery

    antithrombotics in DVT prophylaxis for orthopedic surgery

    direct antithrombins in DVT prophylaxis for all type of patients

    new anticoagulants in DVT prophylaxis for elective major knee surgery

    new anticoagulants in DVT prophylaxis for orthopaedic surgery

    new anticoagulants in DVT prophylaxis for all type of patients



    Reference(s)

    Trials register # NA
    • Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.. J Thromb Haemost 2007;5:2178-85 - 10.1111/j.1538-7836.2007.02748.x
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend